Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Gilead led the global infectious diseases space in 2017
  2. AAD 2018: strong Phase IIb results for upadacitinib in atopic dermatitis
  3. ORIC Pharma to advance ORIC-101 against treatment-resistant cancers
  4. Takeda and Wave Life Sciences to develop neurological treatments
  5. AAD 2018: Is Tremfya more cost-effective than Cosentyx and Taltz?

Latest Content

Phase I Study of Bromodomain Inhibitor OTX015

This white paper describes the methods and findings of a dose-escalation, open-label, pharmacokinetic, Phase I study of bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma. 

AAD 2018: Is Tremfya more cost-effective than Cosentyx and Taltz?

At the 76th annual meeting of the American Academy of Dermatology, Johnson & Johnson (J&J) released a cost per responder analysis of their interleukin 23 subunit alpha (IL-23A) inhibitor Tremfya (guselkumab) compared with Novartis’ IL-17 inhibitor Cosentyx (secukinumab) and Eli Lilly’s IL-17A inhibitor Taltz (ixekizumab) for the treatment of moderate to severe plaque psoriasis (PsO).

Biogen continues to dominate the neurology market

Among the top 10 players in neurology, Biogen is the only company that generated more than 50% of its total sales from neurology products, the vast majority of which are derived from its broad multiple sclerosis (MS) portfolio, including Tecfidera, Avonex, and Tysabri.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top